Alexion Pharmaceuticals, Inc. · 1 day ago
Analytical Development Intern (Graduate-Level)
Alexion Pharmaceuticals, Inc. is seeking Master's and Doctoral students for a 12-week Analytical Development Intern role at their New Haven, CT site. The intern will lead and execute comparability and forced degradation studies, develop and optimize analytical methods for biotherapeutic candidates, and perform characterization of protein variants.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
Lead and execute comparability and forced degradation studies, including study design, sample preparation, data analysis, and reporting
Lead and perform enrichment, fractionation, and characterization of protein variants (e.g., charge and size variants) using techniques such as SEC, CE-SDS, IEX, and MS
Develop, optimize, and document analytical/characterization methods for biotherapeutic candidates, including drafting protocols/reports and establishing system suitability/acceptance criteria
Qualification
Required
Master's and Doctoral students studying Biochemistry, Chemistry or Analytical Chemistry, Chemical Engineering, Molecular Biology, Pharmaceutical Science, Bioengineering/Biotechnology, or a related discipline
Candidates must have an expected graduation date after August 2026
Basic laboratory skills such as pipetting and dilution required
US Work Authorization is required at time of application
Ability to report onsite to New Haven, CT site 4-5 days per week. This role will not provide relocation assistance
Preferred
Knowledge and understanding of separation science, including liquid chromatography (Size-Exclusion Chromatography, Ion-Exchange Chromatography)/Capillary Isoelectric Focusing/Imaged Capillary Electrophoresis is preferred
Enthusiasm for collaboration, cross-functional projects, public speaking, and presentation design
Company
Alexion Pharmaceuticals, Inc.
Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community.
Funding
Current Stage
Public CompanyTotal Funding
$5.8M2020-12-12Acquired
1999-02-12Post Ipo Equity· $5.8M
1996-02-29IPO
Leadership Team
Recent News
bloomberglaw.com
2025-12-20
Company data provided by crunchbase